ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08).

Cash and cash equivalents were $9.5 million as of December 31, 2021.

For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.